Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial
Pignata, Sandro, Dr, Lorusso, Domenica, MD, Scambia, Giovanni, Prof, Sambataro, Daniela, MD, Tamberi, Stefano, MD, Cinieri, Saverio, MD, Mosconi, Anna M, MD, Orditura, Michele, MD, Brandes, Alba A, MD, Arcangeli, Valentina, MD, Panici, Pierluigi Beneditti, Prof, Pisano, Carmela, MD, Cecere, Sabrina C, MD, Di Napoli, Marilena, MD, Raspagliesi, Francesco, MD, Maltese, Giuseppa, MD, Salutari, Vanda, MD, Ricci, Caterina, MD, Daniele, Gennaro, MD, Piccirillo, Maria Carmela, MD, Di Maio, Massimo, MD, Gallo, Ciro, Prof, Perrone, Francesco, MD
Published in The lancet oncology (01.05.2015)
Published in The lancet oncology (01.05.2015)
Get full text
Journal Article